Asia Pacific Castrate-Resistant Prostate Cancer Market Size

Asia Pacific Castrate-Resistant Prostate Cancer Market By Therapy (Hormonal Therapy, Immunotherapy, Chemotherapy and Radiotherapy), By Country, Industry Analysis and Forecast, 2020 - 2026

Asia Pacific Castrate-Resistant Prostate Cancer Market By Therapy (Hormonal Therapy, Immunotherapy, Chemotherapy and Radiotherapy), By Country, Industry Analysis and Forecast, 2020 - 2026

Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support

Published Date : February-2021 | Number of Pages : 65 | Format : PDF

COVID-19

Get in-depth analysis of the COVID-19 impact on the Asia Pacific Castrate-Resistant Prostate Cancer Market

The Asia Pacific Castrate-resistant Prostate Cancer Market would witness market growth of 9.6% CAGR during the forecast period (2020-2026). In the Asia Pacific, the market for castrate-resistant prostate cancer is estimated to propel at a significant rate over the forecast period. It is due to the presence of key oncology companies and rising R&D investments in countries like China and Japan. On the other hand, it led to the increasing development of prostate cancer drugs. Furthermore, the cost of clinical trials is less in developing countries than in developed countries.

Chemotherapy is considered as the first treatment for Castrate-resistant Prostate Cancer (CRPC). It is one of the choices for treatment for CRPC. The approved chemotherapy drugs include docetaxel (Taxotere) with prednisone. Growing advancements in chemotherapy resulted in the formulation of second-line treatment with extending survival in mCRPC patients whose disease advanced after or during docetaxel therapy.

The advancement in technology for diagnostic tests for detecting prostate cancer is also estimated to propel the growth of global market of castration-resistant prostate cancer treatment. Although, the lack of awareness and unavailability of appropriate healthcare facilities in some emerging countries will restrict the market demand for castration-resistant prostate cancer treatment.

Based on Therapy, the market is segmented into Hormonal Therapy, Immunotherapy, Chemotherapy and Radiotherapy. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

Free Valuable Insights: Castrate-Resistant Prostate Cancer Market in Asia Pacific is expected to register a CAGR of 9.6% during the forecast period (2020-2026)

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Sanofi S.A., Johnson and Johnson, Pfizer, Inc., Bayer AG, Abbott Laboratories, GlaxoSmithKline PLC (GSK), Northwest Biotherapeutics, Inc., Active Biotech AB, Astellas Pharma, Inc. and Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)

Scope of the Study

Market Segments Covered in the Report:

By Therapy

  • Hormonal Therapy
  • Immunotherapy
  • Chemotherapy
  • Radiotherapy

By Country

  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific

Companies Profiled

  • Sanofi S.A.
  • Johnson and Johnson
  • Pfizer, Inc.
  • Bayer AG
  • Abbott Laboratories
  • GlaxoSmithKline PLC (GSK)
  • Northwest Biotherapeutics, Inc.
  • Active Biotech AB
  • Astellas Pharma, Inc.
  • Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)

Unique Offerings from KBV Research

  • Exhaustive coverage
  • The highest number of market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Castrate-Resistant Prostate Cancer Market Related Reports:

Global Market

North America Market

Europe Market

LAMEA Market


Purchase Report

 1500
 1800
 2520

Special Pricing & Discounts

  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities